This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MarketVIEW: Clostridium Difficile Vaccines (West)

NEW YORK , Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: MarketVIEW: Clostridium difficile vaccines (West) http://www.reportlinker.com/p0961711/MarketVIEW-Clostridium-difficile-vaccines-West.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Clostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients experience fever, tachycardia and psuedomembranous colitis. Risk factors for C.diff infections are >65 yrs of age, hospitalization, severe underlying illness coupled with chronic antibiotic therapy. Although CDAD can be managed usually by stopping antibiotic therapy or the use of metronidazole and vancomycin treatment, patient mortality can still reach 6-30%. In some patients with toxic megacolon who require surgical intervention or colectomy, mortality can reach even higher rates of 35-50%. 

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of C.diff vaccines to 2030 in the major Western markets. All three potential vaccine indications are modelled: Community prophylaxis (PX), Hospital prophylaxis (PX) and preventation of CDI recurrences (TX) with a focus on key target populations and latest predicted profile profiles. Also included is an in-depth epidemiology forecast to 2030 including number of CDI cases per country drawing upon latest surveillance data (pan-European survey). A discussion of the potential impact of latest pipeline developments/launches e.g. Fidoxamicin (OPT-80) and MK-3415A (monoclonals) on the vaccine proposition is covered. THIS PRODUCT IS AN EXECUTIVE PRESENTATION + 3 MODELS Contents – Executive presentation (MS PowerPoint based)Author's noteExecutive summaryKey commercial outputs: Community PX productKey commercial outputs: Hospital PX productKey commercial outputs: prevention of relapses (TX)Overview of latest changes – February 2012Epidemiology forecast – latest dataEpidemiology: number of CDI cases (2008-2030)Epidemiology: incidence per country 2000-2030Epidemiology: possible scenarios to 2030C.diff vaccines: Epidemiology: possible scenarios to 2030C.Diff vaccines: three potential markets modelledC.Diff vaccines: example target populationsCommunity prophylaxis: major model assumptionsPrevention of CDI recurrences: major model assumptionsHospital prophylaxis: major model assumptionsCommunity prophylaxis: available market ($000s) to 2030Community prophylaxis: competitor revenues ($000s) to 2030Prevention of CDI recurrences: available market ($000s) to 2030Prevention of CDI recurrences: competitor revenues ($000s) to 2030Hospital prophylaxis: available market ($000s) to 2030Hospital prophylaxis: competitor revenues ($000s) to 2030Markets covered to 2030Pricing assumptions appliedCompetitor landscape: overviewSanofi Pasteur: ACAM-CDIFFACAM-CDIFF clinical development planIntercell AG: IC84AntibioticsMonoclonal antibodiesEpidemiology: situation overviewAcute care hospitals: USLTCFs: USAcute care hospitals: pan-EuropeanAcute care hospitals: UK ( Scotland, Wales and N.I.)Acute care hospitals: GermanyAcute care hospitals: FranceAcute care hospitals: SpainAcute care hospitals: ItalyAcute care hospitals: CanadaAcute care hospitals: AustraliaEpidemiology: forecast trendsDefinitions of CDI exposuresFollow-on vaccines: market share analysisBibliographyDisclaimerAbout VacZine AnalyticsPAGES: ~95 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model(s) (MS Excel-based)Note: Three models are included with this productHospital vaccination (PX)Community vaccination (PX)Prevention of CDI replases (TX)United StatesCanadaUKFranceGermanyItalySpainOther EU

To order this report:: MarketVIEW: Clostridium difficile vaccines (West)

Nicolas BombourgReportlinkerEmail: nicolasbombourg@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs